ROME - COMPASS

COMPASS (Cardiovascular OutcoMes for People using Anticoagulation StrategieS) is a large, simple randomized controlled trial for the prevention of cardiovascular events in patients with coronary artery disease (CAD) or peripheral artery disease (PAD).

This study will enroll approximately 20,000 people from more than 400 sites across more than 25 countries. The primary objectives are to determine whether rivaroxaban 2.5 mg twice daily (bid) + aspirin 100 mg once daily (od) compared with aspirin 100 mg od reduces the risk of a composite of myocardial infarction, stroke, or cardiovascular death in subjects with CAD or PAD, whether rivaroxaban 5 mg bid compared with aspirin 100 mg od reduces the risk of a composite of myocardial infarction, stroke or cardiovascular death in subjects with CAD or PAD, and whether pantoprazole 40 mg od compared with placebo reduces the risk of upper gastrointestinal bleeding, ulceration, and gastrointestinal obstruction or perforation in subjects with CAD or PAD receiving antithrombotic medications.

	Email Project Office: compass@phri.ca or contact your SMC
	Phone Project Office: Click here for the toll-free helpline for your country or contact your SMC